Home › Trials › NCT06834100

GNG-DE meningococcal vaccine compared with the reference vaccine

Simple Blinded Multicenter Randomized Comparative Study to Assess Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE

Phase 3 Interventional NPO Petrovax · NCT06834100

This trial will test whether the GNG-DE conjugate vaccine produces a strong immune response and has acceptable side effects in people aged 3 to 55 to prevent meningococcal A, C, W, and Y infections.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment240 (estimated)
Ages3 Years to 55 Years
SexAll
SponsorNPO Petrovax Industry-sponsored
Locations17 sites (Kirov and 16 other locations)
Trial IDNCT06834100 on ClinicalTrials.gov

What this trial studies

This is a phase 3 interventional trial comparing the immunogenicity, reactogenicity, and safety of the GNG-DE polysaccharide conjugate vaccine against a reference meningococcal vaccine. Children and adults aged 3–55 will be enrolled and receive either GNG-DE or the reference product, with follow-up to measure antibody responses and record local or systemic reactions and adverse events. The vaccine targets meningococcal serogroups A, C, W, and Y. The trial is conducted at multiple clinical research centers in Russia.

Who should consider this trial

Good fit: Ideal candidates are healthy children and adults aged 3–55 without contraindications to vaccination who can consent (or whose parent/guardian can consent) and comply with study visits.

Not a fit: People outside the 3–55 age range, those with contraindications to vaccination, or pregnant individuals are unlikely to benefit from participating.

Why it matters

Potential benefit: If successful, GNG-DE could provide an effective and safe alternative vaccine option to prevent meningococcal A, C, W, and Y infections.

How similar studies have performed: Meningococcal polysaccharide-conjugate vaccines against A, C, W, and Y are an established approach and have shown effectiveness in prior studies and public health use.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Male and female subjects aged 3-55 years old inclusive at the time of screening beginning.
2. Availability of a signed Volunteer Informed Consent Form (Volunteer Information Sheet, VIS) (for participants aged 7-55 years inclusive) and/or the parent/adoptive parent informed consent form (Parent Information Sheet, PIS) signed by one of parents/adoptive parents (for participants aged 3-17 years old inclusive).
3. Negative result of SARS-CoV-2 antigen rapid test at screening.
4. Negative pregnancy test result in fertile females of reproductive age. For females not reached puberty, and for girls/women unable to childbirth (with past infertility, hysterectomy, bilateral oophorectomy, bilateral tubal ligation, menopause for more than 2 years), the pregnancy test shall not be performed.
5. For participants of 14-55 years old inclusive with preserved reproductive function, the consent to use of reliable methods of contraception (abstinence, condoms in combination with spermicide and/or hormonal contraception) during the study.

   For participants aged 3-13 years old inclusive and females incapable of childbearing, the consent to use reliable methods of contraception is not required.
6. The consent of a participant and/or a parent/an adoptive parent of a participant to cooperate in good faith with the investigator and the center staff, come to appointed visits, fill out the observation diary and comply with the requirements of the Protocol.

Exclusion Criteria:

1. Hypersensitivity to any component of the test/reference drug.
2. Evident severe systemic reactions to any vaccines in anamnesis.
3. Impossibility of intramuscular injections.
4. Changes in the skin (pigmentation, tattoo, scars etc.) at the planned injection site of the test/reference drug (the deltoid muscle area).
5. Acute infectious and non-infectious diseases, exacerbation of chronic diseases at screening or less than 14 days before screening.
6. Body temperature measured in the armpit ≥ 37.0°C at Visits 0 and 1.
7. The history of chronic diseases that are significant in the opinion of the investigator (for example, malignant neoplasms, blood diseases, autoimmune diseases, immunodeficiencies, etc.).
8. The history of meningococcal infection.
9. Contact with a person with the confirmed infection caused by N. meningitidis less than 2 months before screening.
10. The history of convulsive syndrome or the advanced neurological disease.
11. The history of Guillain-Barré syndrome.
12. The history of mental diseases.
13. Drug administration:

    * the history of meningococcal mono- or polyvalent vaccine, influenza vaccine within 14 days before screening, other vaccines within 30 days before screening;
    * immunostimulants less than 30 days before screening;
    * the immunosuppressive therapy, including systemic corticosteroids, prescribed for more than 5 days, or in the daily dose of more than 1 mg/kg/day of prednisolone or its equivalent - less than 30 days before screening;
    * antipyretics, analgesics - for less than 24 hours before Visits 0 and 1;
    * systemic antibacterial drugs-- for less than 72 hours before Visits 0 and 1;
    * anticoagulants - for less than 3 weeks before Visits 0 and 1;
    * immunoglobulins, blood or plasma products - for less than 3 months before Visits 0 and 1.
14. Planning the administration of vaccines with the exception of the test/reference drug during the clinical study.
15. Surgical interventions performed less than 3 months before screening.
16. Participation in another clinical study less than 30 days before screening.
17. Other conditions that, in the opinion of the investigator, interfere to the enrollment.

Where this trial is running

Kirov and 16 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions InfectionsMeningococcal
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.